Clinical Trials Logo

Clinical Trial Summary

Metoprolol is frequently administered to cardiac surgery patients to reduce the incidence of postoperative atrial fibrillation (PoAF). Metoprolol is metabolized by the enzyme CYP2D6, which is known to have many mutations that could influence a patient's ability to metabolize the drug. In this prospective clinical trial, the investigators will determine the genotype of CYP2D6 for patients undergoing cardiac surgery, provide an altered dosing recommendation for metoprolol, then report the relative effectiveness in managing PoAF for each pharmacogenetic- guided dosing category. The investigators will also explore the effects of personalized metoprolol dosing recommendations on outcomes in hospital length of stay, cost, and provider participation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03943927
Study type Interventional
Source Vanderbilt University Medical Center
Contact
Status Completed
Phase N/A
Start date March 5, 2021
Completion date November 20, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05223725 - Gene Therapy for Post-Operative Atrial Fibrillation Phase 1
Recruiting NCT06124937 - Empagliflozin to Prevent Post-Operative Atrial Fibrillation Phase 3
Completed NCT03779841 - Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA) Phase 2
Recruiting NCT04993456 - Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation
Completed NCT03525860 - Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting N/A
Completed NCT02701062 - AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS) Phase 4
Recruiting NCT02029534 - Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Phase 4